Objectif Despite the advent of the antibiotic era, infectious diseases retain their pre-eminent position as major worldwide causes of morbidity and mortality. This problem has been worsen by the emergence of multi-antibiotic resistant bacteria and the failure of Pharmaceutical company drug discovery programmes to design antibiotics with truly novel modes of action. NABATIVI has put together a unique consortium made of six academic insitutions and three highly recognized SMEs with complementary expertise in the fields of molecular pathogenicity and broad expertise in drug discovery, optimisation, preclinical development. The consortium has been specifically designed to generate new strategies leading to the identification and validation of novel targets for antimicrobials using as model organisms the gram-negatives Pseudomonas aeruginosa and Burkholderia cenocepacia as they are key agents of morbidity and mortality worldwide in a wide range of diseases. The versatility of these model bacteria will enable the results obtained to be extrapolated to other bacterial pathogens. The extensive involvement of SMEs in this consortium will enable the selection of lead compounds against the identified targets from their large libraries of natural and synthetic chemicals which after validation will establish the basis for the development of new classes of antibacterial drugs. This will result in a reduction in the incidence and improvement of the treatment of infections caused by these organisms with a direct impact on the quality of life and the life expectancy of the affected risk patient populations. Champ scientifique sciences médicales et de la santémédecine fondamentalepharmacologie et pharmaciedécouverte de médicamentssciences socialessociologiedémographiemortalitésciences naturellessciences biologiquesmicrobiologiebactériologiesciences médicales et de la santésciences de la santémaladie infectieusesciences médicales et de la santémédecine fondamentalepharmacologie et pharmacieproduit pharmaceutiqueantibiotique Mots‑clés Gram negative bacteria antibacterial antimicrobial resistance lead compound novel drug target Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH-2007-2.1.2-5 - Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and diseases HEALTH-2007-2.3.1-1 - Novel targets for drugs against Gram negative bacteria Appel à propositions FP7-HEALTH-2007-B Voir d’autres projets de cet appel Régime de financement CP-FP - Small or medium-scale focused research project Coordinateur UNIVERSITA VITA-SALUTE SAN RAFFAELE Adresse Via olgettina 58 20132 Milano Italie Voir sur la carte Type d’activité Higher or Secondary Education Establishments projects.administrative_contact Maria Rosa Pedrazzi (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Contribution de l’UE € 610 529,00 Participants (9) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire THE UNIVERSITY OF NOTTINGHAM GB Contribution de l’UE € 681 600,00 Adresse University park NG7 2RD Nottingham Voir sur la carte Type d’activité Higher or Secondary Education Establishments projects.administrative_contact Paul Cartledge (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window EBERHARD KARLS UNIVERSITAET TUEBINGEN Allemagne Contribution de l’UE € 618 960,00 Adresse Geschwister-scholl-platz 72074 Tuebingen Voir sur la carte Type d’activité Higher or Secondary Education Establishments projects.administrative_contact Gerd Döring (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window ACTAR AB Suède Contribution de l’UE € 524 860,00 Adresse Nobels vaeg 3 171 77 Stockholm Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) projects.administrative_contact Eva Montgomerie (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window University of Zurich Suisse Contribution de l’UE € 674 800,00 Adresse Ramistrasse 71 8006 Zurich Voir sur la carte Type d’activité Higher or Secondary Education Establishments projects.administrative_contact John Robinson (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window UNIVERSITA DEGLI STUDI DI MILANO Italie Contribution de l’UE € 699 600,00 Adresse Via festa del perdono 7 20122 Milano Voir sur la carte Type d’activité Higher or Secondary Education Establishments projects.administrative_contact Stefania Varotto (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window GREENPHARMA S.A. France Contribution de l’UE € 527 600,00 Adresse Allée du titane 3 45100 Orléans Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) projects.administrative_contact Jean-Yves Berthon (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window KOBENHAVNS UNIVERSITET Danemark Contribution de l’UE € 522 880,00 Adresse Norregade 10 1165 Kobenhavn Voir sur la carte Type d’activité Higher or Secondary Education Establishments projects.administrative_contact Ivan Kristoffersen (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Polyphor AG Suisse Contribution de l’UE € 341 500,00 Adresse Hegenheimermattweg 4123 Allschwil Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) projects.administrative_contact Christian Ludin (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window FONDAZIONE CENTRO SAN RAFFAELE Italie Contribution de l’UE € 303 671,00 Adresse Via olgettina 60 20132 Milano Voir sur la carte Type d’activité Research Organisations projects.administrative_contact Maria Rosa Pedrazzi (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window
